Miniaturized, Ultra-High Throughput Screening of Tyrosine Kinases Using Homogeneous, Competitive Fluorescence Immunoassays
- 1 April 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in ASSAY and Drug Development Technologies
- Vol. 2 (2) , 141-151
- https://doi.org/10.1089/154065804323056486
Abstract
Assay miniaturization and the implementation of high-density 1,536-microwell screening increase the speed and efficiency of screening and lead discovery. To serve this need, a platform of miniaturizable assay technologies has been assembled for specific biological targets. This platform will enable initiation and completion of uHTS screens in a straightforward and expeditious manner. Although faster primary screening does contribute to a reduction in timelines, the process of assay development can become a bottleneck. Assay technologies that do not require the use of target-specific reagents can reduce the time necessary for assay development. Assays that measure inhibition of tyrosine kinases can be configured in a competitive format where only the enzyme itself is specific to the assay. In this context, several technologies, including time-resolved fluorometry (also known as DELFIA), time-resolved fluorescence resonance energy transfer (also known as LANCE( trade mark )), fluorescence polarization, enzyme fragmentation complementation assay, and confocal laser scanning imaging, were examined. Quality parameters such as assay reproducibility, signal:background ratio, Z factor, and assay sensitivity were compared. Additionally, the relative merits of each of these technologies are assessed in terms of assay miniaturization, ease of development, ultimate screening capability, efficiency, and cost.Keywords
This publication has 15 references indexed in Scilit:
- Determining Appropriate Substrate Conversion for Enzymatic Assays in High-Throughput ScreeningSLAS Discovery, 2003
- A Homogeneous Fluorescence Polarization Assay Adaptable for a Range of Protein Serine/Threonine and Tyrosine KinasesSLAS Discovery, 2003
- Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2003
- 1,536-Well Assay Development and Screening Using Whole Cell Displacement Binding and Laser Scanning ImagingASSAY and Drug Development Technologies, 2003
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Enzyme Fragment Complementation: A Flexible High Throughput Screening Assay TechnologyASSAY and Drug Development Technologies, 2002
- Development of a 1-μl Scale Assay for Mitogen-Activated Kinase Kinase 7 Using 2-D Fluorescence Intensity Distribution Analysis AnisotropySLAS Discovery, 2002
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Tyrosine kinase assays adapted to homogeneous time-resolved fluorescenceDrug Discovery Today, 1998
- Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton.The Journal of cell biology, 1989